What is the Fiscal Year for Nuvectis Pharma?
Date: November 14, 2026
Nuvectis Pharma's current fiscal year starts on January 1, 2026, and ends on December 31, 2026. Their current quarter is Q4, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
January 1, 2026
Fiscal Year End
December 31, 2026
Current Quarter
Q4
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Jan 1, 2026 – Mar 31, 2026
Q2
Apr 1, 2026 – Jun 30, 2026
Q3
Jul 1, 2026 – Sep 30, 2026
Q4
Oct 1, 2026 – Dec 31, 2026
Company Information
Headquarters
Jersey
Industry
Biotechnology Research
Stock Symbol
NVCT
Website
https://nuvectis.com/Description
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We are developing two drug candidates, NXP800 and NXP900: NXP800 is an oral small molecule that exerts its biologic activity through activation of the kinase GCN2. NXP800 is currently investigated in a clinical trial for the treatment of platinum resistant, ARID1a-mutated ovarian cancer, a development program that was granted Fast Track Designation by the U.S. FDA, and for the treatment of cholangiocarcinoma in an investigator-sponsored clinical trial led by Mayo clinic, an indication that was granted Orphan Drug Designation by the U.S. FDA. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 is currently investigated in a Phase 1 dose escalation clinical trial.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Nuvectis Pharma and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.